January 29, 2018 / 7:11 AM / 10 months ago

BRIEF-Bergenbio: ‍Favourable Data Reported Across Three Phase II Clinical Trials

Jan 29 (Reuters) - BERGENBIO ASA:

* BERGENBIO: ENCOURAGING I-O CLINICAL DATA WITH SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324) SUPPORTS ITS POTENTIAL AS CORNERSTONE OF CANCER THERAPY

* ‍FAVOURABLE INTERIM SAFETY DATA REPORTED ACROSS THREE PHASE II CLINICAL TRIALS WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below